<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01187238</url>
  </required_header>
  <id_info>
    <org_study_id>CH-HN-001</org_study_id>
    <nct_id>NCT01187238</nct_id>
  </id_info>
  <brief_title>The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Randomized Multicenter Phase II Study of Intensity-modulated Radiotherapy Combined With Chemotherapy Versus Intensity-modulated Radiotherapy Alone for Stage II Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to verify the role of adding cisplatin chemotherapy to the
      intensity-modulated radiotherapy (IMRT) for stage II nasopharyngeal carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical Stage II nasopharyngeal carcinoma consisted of T2N0M0, T1N1M0, T2N1M0 three
      subgroups, the data came from conventional radiotherapy era showed that the prognosis of this
      three subgroups were different, the N1 groups suffered more distant metastasis than N0 group,
      and some literature showed that combined chemotherapy with radiotherapy in stage II patients
      can improve the treatment results.

      Intensity-modulated radiotherapy (IMRT)now is an widely used technique in the treatment of
      nasopharyngeal carcinoma, the preliminary results showed that IMRT can improve the quality of
      life in nasopharyngeal through salivary gland preservation.

      Compared IMRT alone with IMRT plus cisplatin concurrent chemotherapy in the treatment of
      stageII nasopharyngeal carcinoma, we hope to confirm whether stage II (and which subgroup)
      nasopharyngeal carcinoma will be benefit from concurrent chemoradiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicities</measure>
    <time_frame>2 years</time_frame>
    <description>Acute toxicity will be measured by CTCAE3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long term treatment results</measure>
    <time_frame>5 years</time_frame>
    <description>1-, 3-year local-regional control, overall survival, disease-free survival, distant metastasis-free survival will be observed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm1-radical radiotherapy alone group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Arm1-radical radiotherapy alone group, the eligibility patients will received radical intensity-modulated radiotherapy alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm2-concurrent chemoradiotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm2-concurrent chemoradiotherapy group, the eligibility patients will received radiotherapy the same as radical radiotherapy arm,and also will received the concurrent chemotherapy wiht the regimen consist of cisplatin 40mg/m2, weekly for 7weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>in experimental arm, the eligibility patients will be received the same radiotherapy as radical radiotherapy alone group, and also will received concurrent chemotherapy with the regimen of cisplatin 40mg/m2, weekly,from week 1 to week 7</description>
    <arm_group_label>Arm2-concurrent chemoradiotherapy group</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathological confirmed squamous cell carcinoma, WHO II-III type,

          -  clinical stage II (UICC 7th edition, 2009)

          -  Karnovsky performance score &gt; 70

          -  first course of radiotherapy, without radiotherapy and chemotherapy history for other
             head and neck cancer.

          -  anticipated life span more than 6 month

          -  Hemoglobin &gt; 120g/L, WBC &gt; 4.0x10*9/L, Plt &gt; 100x10*9/L

          -  liver and renal function under the 1.25 normal upper limit

          -  with written consent information

        Exclusion Criteria:

          -  have other cancer history

          -  have chemotherapy history

          -  have radiotherapy history

          -  have head and neck surgery history(exclusion lymph node biopsy)

          -  evidence showed distant metastasis or other cancer

          -  other severe medical comorbidity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Gao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang province cancer hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kam MK, Leung SF, Zee B, Chau RM, Suen JJ, Mo F, Lai M, Ho R, Cheung KY, Yu BK, Chiu SK, Choi PH, Teo PM, Kwan WH, Chan AT. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007 Nov 1;25(31):4873-9.</citation>
    <PMID>17971582</PMID>
  </reference>
  <reference>
    <citation>Chua DT, Sham JS, Kwong DL, Au GK. Treatment outcome after radiotherapy alone for patients with Stage I-II nasopharyngeal carcinoma. Cancer. 2003 Jul 1;98(1):74-80.</citation>
    <PMID>12833458</PMID>
  </reference>
  <results_reference>
    <citation>Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, Lu TX, Au GK, Min HQ. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials. Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1300-6. Epub 2006 Jun 5.</citation>
    <PMID>16750333</PMID>
  </results_reference>
  <results_reference>
    <citation>Cheng SH, Tsai SY, Yen KL, Jian JJ, Chu NM, Chan KY, Tan TD, Cheng JC, Hsieh CY, Huang AT. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol. 2000 May;18(10):2040-5.</citation>
    <PMID>10811668</PMID>
  </results_reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2010</study_first_posted>
  <last_update_submitted>September 9, 2014</last_update_submitted>
  <last_update_submitted_qc>September 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Li Gao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal carcinoma</keyword>
  <keyword>Stage II</keyword>
  <keyword>Intensity-modulated radiotherapy</keyword>
  <keyword>Concurrent chemoradiotherapy</keyword>
  <keyword>Cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

